Critical Pharmacodynamic Warning

cerivastatin affects the 2C8 metabolic pathway.

When patients take cerivastatin concurrently with drugs metabolized by 2C8, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Impact: As a in-vitro only, cerivastatin can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.

Clinical Overview for cerivastatin

This page outlines known interaction pathways involving cerivastatin, focusing primarily on its profile as a In-Vitro Only affecting the 2C8 pathway.

Enzyme Interaction Profile

cerivastatin demonstrates in-vitro only potency against 2C8. Clinical significance of this interaction requires further evaluation.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: cerivastatin affects 2C8

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Interaction Details
Drug Name cerivastatin
Affected Enzyme 2C8
Inhibitor Strength In-Vitro Only Laboratory Evidence
Inducers No inducers listed
Inhibitors montelukast
Clinical Recommendations

Evidence from laboratory studies only. Clinical significance unknown.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
8261
Primary Pathway
2C8
Interaction Type
Enzyme Inhibition
Clinical Phase
Laboratory Evidence
Clinical Significance

Clinical significance requires further evaluation.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies
Last updated: June 19, 2026
Back Return to Database